Tirzepatide

Aliases: LY3298176 · GIP/GLP-1 dual agonist

Tirzepatide is a linear peptide targeting GLP-1R, GIPR, developed by Eli Lilly for multiple indications. As of Aug 15, 2024, its highest verified stage is Approved.

Approved· verified Aug 15, 2024

Identity

Generic name: tirzepatide
Brand names: Mounjaro, Zepbound
Development codes: LY3298176
Sponsor / originator: Eli Lilly
Targets: GLP-1R GIPR
Route / formulation: Subcutaneous injection

Development timeline

Phase 3· Cardiovascular risk reduction· United States
As of Aug 15, 2024 · Confidence: high
Source: SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetesSURMOUNT-MMOE evaluating cardiovascular outcomes ongoing.
Approved· Type 2 diabetes· United States
As of Aug 15, 2024 · Confidence: high
Source: FDA approves Mounjaro (tirzepatide) for adults with type 2 diabetesFDA approved as Mounjaro for type 2 diabetes.
Approved· Obesity· United States
As of Aug 15, 2024 · Confidence: high
Source: FDA approves Mounjaro (tirzepatide) for adults with type 2 diabetesFDA approved as Zepbound for chronic weight management.

Trials

View all →

Registry ID	Phase	Status	Enrollment	Completion
NCT03954834	Phase 3	Completed	1876	Apr 29, 2021
NCT04159132	Phase 3	Completed	2539	Jul 1, 2022

Readouts

View all →

Clinical trial registry and NEJM publication

Tirzepatide SURPASS-2 delivers superior HbA1c and weight reductions vs semaglutide 1 mg

Aug 5, 2021

Regulatory approvals

Jurisdiction	Brand	Indication	Date
United States	Mounjaro	Type 2 diabetes	May 13, 2022
United States	Zepbound	Obesity	Nov 8, 2023

Deals

View all →

licensing

Eli Lilly and Company / Chugai Pharmaceutical Co., Ltd.

Not disclosed (contingent)

Next catalysts

View all →

readout · company guidance

Topline data from SURMOUNT-MMOE cardiovascular outcomes trial expected 2025.

Jan 1, 2025 – Jun 30, 2025

Sources

registryprimary record
SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes
Eli Lilly and Company · ClinicalTrials.gov · May 17, 2019 · NCT03954834
registryprimary record
SURMOUNT-4: Tirzepatide after intensive lifestyle intervention
Eli Lilly and Company · ClinicalTrials.gov · Nov 21, 2019 · NCT04159132
regulatoryprimary record
FDA approves Mounjaro (tirzepatide) for adults with type 2 diabetes
U.S. Food and Drug Administration · FDA News Release · May 13, 2022
peer-reviewedpeer-reviewed
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Frías JP et al. · New England Journal of Medicine · Aug 5, 2021 · DOI: 10.1056/NEJMoa2107519 · PMID: 34379988